Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...

It is probably fair to say that we can still do much more to ensure that all the meetings and events we organise or attend, ...

Major players from across the UK’s health and life sciences sector have responded to the Autumn Budget delivered by Labour ...

Novartis’ Scemblix (asciminib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a ...

AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design ...

Every year, the medical community recognizes the month of November as Clostridioides difficile (C. diff) Awareness month. C.

Pharma companion apps are transforming healthcare by offering support beyond traditional treatments, enhancing patient ...

BeiGene’s Tevimbra (tislelizumab) has been recommended by the European Medicines Agency’s human medicines committee as a first-line treatment for gastric and oesophageal cancer patients. The Committee ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

Merck & Co – known as MSD outside the US and Canada – has acquired Yale University oncology spinout Modifi Biosciences in a deal worth $1.3bn. The agreement gives Merck access to preclinical compounds ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...